

## BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Yvette Leslie Kasamon	POSITION TITLE Assistant Professor of Oncology and Medicine		
eRA COMMONS USER NAME (credential, e.g., agency login) ykasamo1			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Harvard University, Cambridge, MA	A.B.	05/1995	Biology
University of Pittsburgh School of Medicine, PA	M.D.	05/1999	Medicine
Brigham and Women's Hospital, Boston, MA	Internship	05/2000	Internal Medicine
Brigham and Women's Hospital, Boston, MA	Residency	05/2005	Internal Medicine
Johns Hopkins University, Baltimore, MD	Fellowship	05/2005	Hematology-Oncology

### A. Personal Statement

I am a clinical researcher with a focus on translational research and the role of image-guided therapies. I have developed, written and led a number of clinical trials incorporating early PET-CT after 2-3 cycles of chemotherapy to guide the next therapeutic steps (change chemo, high dose therapy). I lead the presently approved FIAU tumor imaging trial. I am also active in the care of AIDS Malignancy Patients and lead two AIDS Malignancy Consortium Trials at Johns Hopkins.

### B. Positions and Honors

#### Positions and Employment

2005 Assistant Professor of Oncology and Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

#### Board certifications

2002-12 Internal Medicine  
2005-15 Medical Oncology  
2005-15 Hematology

#### Honors

1994, 95 John Harvard Scholarship for Academic Achievement of the Highest Degree  
1994, 95 Elizabeth Cary Agassiz Scholarship for Academic Achievement of the Highest Degree  
1995 A.B. magna cum laude  
1995 Phi Beta Kappa, Radcliffe Chapter  
1996 Bernard M. Klionsky Fellowship in Pathology  
1996 James Ewing Foundation's Lucy Wortham James Student Research Award in Oncology  
1997 Alpha Omega Alpha Honor Medical Society  
1999 Doctor of Medicine, *cum laude*  
1999 James D. Heard Senior Prize in Medicine  
2003 Scholarship, AACR/ASCO Methods in Clinical Cancer Research workshop  
2005-06 AACR-Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer Research  
2005-06 ASCO Foundation Young Investigator Award  
2008 ASCO Career Development Award (awarded, returned due to concurrent funding)  
2008-13 Recipient, K23 Award

#### Professional committees and memberships

2002 American Society of Hematology  
2002 American Society of Clinical Oncology  
2005-08 Member, ASCO Career Development Committee  
2008 Member, Johns Hopkins Clinical Research Committee  
2009 Member, Education Committee of the Sidney Kimmel Comprehensive Cancer Center

### C. Selected Peer-reviewed Publications (selected from 27 peer-reviewed publications)

#### Most relevant to the current application

1. Tuting T, Wilson CC, Martin D, Kasamon Y, Rowles J, Ma DI, Slingluff CL, Wagner SC, van der Bruggen P, Baar J, Lotze MT, Storkus WJ. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses *in vitro*: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN- $\gamma$ . *Journal of Immunology* 1998; 160: 1139-1147.
2. Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. *Hematology/Oncology Clinics of North America* 2005; 19:665-87.
3. Kasamon YL, Jones RJ, Diehl LF, Nayer H, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RA, Zhang Z, Flinn IW. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. *Biology of Blood and Marrow Transplantation* 2005; 11: 39-46.
4. Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW. High-dose therapy and blood or marrow transplantation for non-Hodgkin's lymphoma with central nervous system involvement. *Biology of Blood and Marrow Transplantation* 2005; 11: 93-100.
5. Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I study of low dose IL-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. *Clinical Cancer Research* 2005; 11: 8413-8417.
6. Kasamon YL, Ambinder RF. Immunotherapies for Hodgkin's lymphoma. *Critical Reviews in Oncology/Hematology* 2008; 66: 135-144. PMC Journal - In Process.
7. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. *Current Opinion in Oncology* 2008; 20:206-19. PMC Journal - In Process.
8. Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, Rogers KM, Bolaños-Meade J, Borowitz MJ, Ambinder RF, Jones RJ, Swinnen LJ. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. *Biology of Blood and Marrow Transplantation* 2009; 15(2):242-8. PMC Journal - In Process.
9. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, Lemas MV, Brennan S, Ambinder RF, Matsui W. Circulating clonotypic B cells in classical Hodgkin's lymphoma. *Blood* 2009; 113(23): 5920-6. Not Funded by NIH.
10. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. *Journal of Nuclear Medicine*, 2009; 50 Suppl 1: 122S-50S.
11. Kasamon Y, Jones RJ, Brodsky RA, Fuchs EJ, Matsui W, Luznik L, Powel JD, Blackford AL, Goodrich A, Gocke CD, Abrams RA, Ambinder RF, Flinn IW. Immunologic recovery following autologous stem cell transplantation with pre- and post-transplantation rituximab for low-grade or mantle cell lymphoma. *Annals of Oncology* 2010; 21:1203-10. PMID2875548 [Available on 2011/6/1].
12. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. *Clinical Cancer Research* 2010; 16: 338-47. PMID2804932 [Available on 2011/1/1].
13. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J, Morris LE, Crilley PA, O'Donnell PV, Rossiter N, Huff CA, Brodsky RA, Matsui WH, Swinnen LJ, Borrello I, Powell JD, Ambinder RF, Jones RJ, Fuchs EJ. Nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. *Biology of Blood and Marrow Transplantation* 2010; 16: 482-9. PMC Journal - In Process.
14. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. *Blood* 2010; 115: 3224-30. PMID2858487 [Available on 2011/4/22].
15. Kasamon YL, Jones RJ, Gocke CD, Blackford AL, Seifter EJ, Davis-Sproul JM, Gore SD, Ambinder RF. Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin's lymphomas. *Biology of Blood and Marrow Transplantation*. Prepublished on-line 2010 Jul 21. PMC Journal - In Process.

## **D. Research Support**

### **Ongoing Research Projects**

2P50CA103175-06A2 (Bhujwalla)

09/22/11-07/31/16

NIH/NCI

JHU ICMIC Program – Research Component 2 – BETR Theranostics for AIDS Kaposi's Sarcoma

The goal is to investigate a novel imaging and therapeutic strategy for Kaposi's sarcoma.

K23 CA124465 (Kasamon)

05/01/08-04/30/13

NIH

Novel Biologic Therapies for Hodgkin's Lymphoma

The major goal is to investigate new therapies for Hodgkin's lymphoma based on cancer stem cell biology.

R01 CA138636 (Pomper, Ambinder)

04/01/10-02/28/14

NCI

BETR Therapy for Herpesvirus-associated Tumors

The major goal of this project is to evaluate a novel imaging method and therapeutic approach for EBV-associated tumors.

K23CA124465 (Kasamon)

05/05/08-04/30/13

NIH

Novel Biologic Therapies for Hodgkin's Lymphoma

The major goal is to investigate new targeted therapies for Hodgkin's lymphoma based on recent biological insights.

P01CA15396 (Jones)

04/05/07-02/28/13

NCI

Bone Marrow Transplantation in Human Disease. Project 3 - Hodgkin's Lymphoma Stem Cells

Project 4 – Harnessing Alloreactivity

The major goal of this project is to characterize Hodgkin's stem cells and other targets for therapy and to investigate strategies for enhancing anti-tumor alloreactivity.

P01CA15396-34S1 (Jones)

09/30/09-09/29/12

NCI

Bone Marrow Transplantation in Human Disease. - Supplement to Project 3

The major goal of this project is to evaluate a novel imaging method for EBV-associated tumors.

SNDX-275-0501(Kasamon)

09/17/09-09/16/12

Syndax

A Phase 2, Multi-center Study of Entinostat (SNDX-275) in Patients with Relapsed or Refractory Hodgkin's Lymphoma

The goal is to examine the efficacy and safety of this drug in relapsed/refractory Hodgkin's lymphoma.

SGN35-005 (Kasamon)

04/29/10-04/28/13

Seattle Genetics

A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

The goal is to evaluate the efficacy of SGN-35 after autologous transplantation for relapsed Hodgkin lymphoma.

R01CA138636 (Pomper/Ambinder)

04/1/10-02/28/14

NIH/NCI

Investigation in a clinical trial of bortezomib-activated therapy in EBV lymphoma.

The goal is to investigate a novel imaging and therapeutic strategy for EBV associated tumors.

**Completed Projects Within Last Three Years**

90040832 (Kasamon)

01/26/10-01/25/12

Genentech, Inc

A randomized phase II study of rituximab with ABVD versus standard ABVD for patients with advanced-stage classical Hodgkin lymphoma with poor risk features (IPS score > 2).

The goal is to compare the efficacy of rituximab-ABVD versus standard therapy for newly diagnosed, poor-risk Hodgkin lymphoma.

PO1 CA15396 (Jones)

04/01/07-02/18/12

NCI

Bone Marrow Transplantation in Human Disease

Project 3: Hodgkin's Lymphoma Stem Cells (Ambinder); Project 4 – Harnessing Alloreactivity

The major goal of this project is to characterize Hodgkin's stem cells and other targets for therapy, and to investigate strategies for enhancing anti-tumor alloreactivity.

P01CA15396-34S1 (Jones)

09/30/09-09/29/11

NCI

Bone Marrow Transplantation in Human Disease. - Supplement to Project 3

The major goal of this project is to evaluate a novel imaging method for EBV-associated tumors and develop assays for evaluating EBV activity.